Latest BRCA1 Stories
A woman's ethnicity as well as her genetic makeup are two of the main risk factors for hereditary breast cancer.
Researchers at Dana-Farber Cancer Institute have demonstrated a molecular strategy they say could make a much larger variety of tumors treatable with PARP inhibitors, a promising new class of cancer drugs.
The genome of the most common form of ovarian cancer is characterized by a few common gene mutations but also surprisingly frequent structural changes in the genome itself.
Women with ovarian cancer who have the BRCA2 gene mutation are more likely to survive the malignancy than women with the BRCA1 mutation, or women without either mutation.
Between 5 % and 10 % of breast cancer cases are hereditary, arising because the patient inherits from the father or mother a mutation in a gene that is susceptible to causing the illness.
Unfortunately, some people are destined for breast cancer.
A new study sheds light on why individuals who inherit a particular family of mutations have a high risk of developing a very aggressive form of breast cancer.
Better physician education and consultation with genetics professionals when recommending genetic testing for healthy relatives of cancer patients could lower costs and increase the value of the testing, said a cancer geneticist from the NCI-designated Dan L. Duncan Cancer Center at Baylor College of Medicine, who surveyed physicians to determine their level of knowledge.
A new drug that targets proteins responsible for helping cancer cells to repair damage to their DNA has shown promising anti-tumour activity in its first trial in humans.
An Australian research team from the Peter MacCallum Cancer Centre, the University of Melbourne and the University of Queensland has identified a new risk factor for developing breast cancer.
- A hairdresser.